Galmed Pharmaceuticals Ltd (GLMD) Expected to Announce Quarterly Sales of $290,000.00

Analysts predict that Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) will announce sales of $290,000.00 for the current quarter, Zacks reports. Four analysts have issued estimates for Galmed Pharmaceuticals’ earnings. The lowest sales estimate is $270,000.00 and the highest is $300,000.00. Galmed Pharmaceuticals posted sales of $270,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 7.4%. The company is scheduled to announce its next earnings report on Monday, July 30th.

According to Zacks, analysts expect that Galmed Pharmaceuticals will report full-year sales of $850,000.00 for the current fiscal year, with estimates ranging from $540,000.00 to $1.17 million. For the next financial year, analysts forecast that the business will report sales of $3.00 million per share. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Galmed Pharmaceuticals.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its earnings results on Wednesday, May 16th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.06. The firm had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.29 million. Galmed Pharmaceuticals had a negative net margin of 1,073.09% and a negative return on equity of 110.46%.

A number of analysts recently issued reports on the stock. HC Wainwright increased their target price on shares of Galmed Pharmaceuticals from $24.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, June 12th. SunTrust Banks increased their target price on shares of Galmed Pharmaceuticals from $15.00 to $31.00 in a research report on Tuesday, June 12th. Maxim Group increased their target price on shares of Galmed Pharmaceuticals from $14.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, June 12th. ValuEngine raised shares of Galmed Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 12th. Finally, Zacks Investment Research raised shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a research report on Tuesday, May 15th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $26.92.

A number of large investors have recently modified their holdings of GLMD. A.R.T. Advisors LLC acquired a new stake in Galmed Pharmaceuticals in the first quarter valued at approximately $107,000. UBS Group AG grew its position in Galmed Pharmaceuticals by 5,334.8% in the first quarter. UBS Group AG now owns 40,000 shares of the biopharmaceutical company’s stock valued at $223,000 after acquiring an additional 39,264 shares in the last quarter. Deutsche Bank AG acquired a new stake in Galmed Pharmaceuticals in the fourth quarter valued at approximately $246,000. Renaissance Technologies LLC acquired a new stake in Galmed Pharmaceuticals in the fourth quarter valued at approximately $345,000. Finally, J. Goldman & Co LP acquired a new stake in Galmed Pharmaceuticals in the fourth quarter valued at approximately $569,000. 17.28% of the stock is owned by institutional investors.

GLMD opened at $14.21 on Thursday. The company has a market cap of $230.14 million, a P/E ratio of -14.50 and a beta of 2.73. Galmed Pharmaceuticals has a 1 year low of $3.61 and a 1 year high of $27.06.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.

Get a free copy of the Zacks research report on Galmed Pharmaceuticals (GLMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply